【摘要】 目的 分析非奈利酮研究的现状热点和发展趋势，为后续研究提供参考和建议。方法 通过检索2012年1月至2024年6月中国知网、维普网、万方数据知识服务平台和Web of Science核心合集数据库中非奈利酮的相关文献，运用CiteSpace 6.3.R1软件对文献的作者、机构、国家/地区和关键词进行可视化分析。结果 纳入中文文献376篇，英文文献433篇；发文量呈逐年上升趋势；中文和英文文献发文量最多的作者分别为汪年松（4篇）和Kolkhof Peter(59篇)；中文和英文文献发文最多的机构为北京中医药大学（9篇）和拜尔集团（107篇）；美国（174篇）、德国（156篇）、希腊（65篇）、丹麦（59篇）、中国（56篇）的发文量较多；中文和英文文献关键词聚类分别为8类和10类，研究热点围绕心力衰竭、糖尿病肾病等展开。结论 非奈利酮近年来尤其是上市后备受国内外研究者们的关注，研究者们可从非奈利酮治疗心力衰竭、糖尿病肾病方向开展研究。更多还原

【Abstract】 Objective To analyze the current hotspots and development trends of Finerenone research, and to provide references and suggestions for subsequent research. Methods The Finerenone relevant literatures collected by CNKI, VIP,Wanfang Data, and Web of Science Core Collection Database from January 2012 to June 2024 were retrieved, using CiteSpace 6.3.R1 software for visual analysis of authors, institutions, countries/regions, and keywords. Results A total of376 articles in Chinese and 433 articles in English were included; the number of publications showed an increasing trend year by year. The authors with the largest number of published papers in Chinese and English were Wang Niansong(4 papers) and Kolkhof Peter(59 papers), respectively. The institutions that published the most Chinese and English literature were Beijing University of Chinese Medicine(9 articles) and Bayer Group(107 articles). The United States(174 articles), Germany(156 articles), Greece(65 articles), Denmark(59 articles), and China(56 articles) had a relatively large number of articles published. The keyword clustering of Chinese and English literature was 8 and 10 categories respectively,and the research hotspots revolved around heart failure, diabetic nephropathy, etc. Conclusion Finerenone has attracted much attention from domestic and foreign researchers in recent years, especially after its release on the market. Researchers can carry out research in the direction of Finerenone treatment of heart failure, diabetic nephropathy.更多还原